911 related articles for article (PubMed ID: 12500203)
1. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
2. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G
J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
[TBL] [Abstract][Full Text] [Related]
4. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
Gerbes AL; Gülberg V; Ginès P; Decaux G; Gross P; Gandjini H; Djian J;
Gastroenterology; 2003 Apr; 124(4):933-9. PubMed ID: 12671890
[TBL] [Abstract][Full Text] [Related]
5. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
[TBL] [Abstract][Full Text] [Related]
6. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Palm C; Pistrosch F; Herbrig K; Gross P
Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
[TBL] [Abstract][Full Text] [Related]
9. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
10. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
[TBL] [Abstract][Full Text] [Related]
11. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
[TBL] [Abstract][Full Text] [Related]
12. Treatment options for hyponatremia in heart failure.
Goldsmith SR
Congest Heart Fail; 2010 Jul; 16 Suppl 1():S15-8. PubMed ID: 20653706
[TBL] [Abstract][Full Text] [Related]
13. The use of vasopressin receptor antagonists in hyponatremia.
Khanna A; Menon MC
Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
[TBL] [Abstract][Full Text] [Related]
14. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.
Rai A; Whaley-Connell A; McFarlane S; Sowers JR
Am J Nephrol; 2006; 26(6):579-89. PubMed ID: 17170524
[TBL] [Abstract][Full Text] [Related]
15. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Ghali JK; Zmily HD; Farah JO; Daifallah S
IDrugs; 2010 Nov; 13(11):782-92. PubMed ID: 21046526
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin antagonists: role in the management of hyponatremia.
Yeates KE; Morton AR
Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
[TBL] [Abstract][Full Text] [Related]
18. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Ferguson JW; Therapondos G; Newby DE; Hayes PC
Clin Sci (Lond); 2003 Jul; 105(1):1-8. PubMed ID: 12639215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]